Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: potassium sorbate; castor oil; titanium dioxide; hypromellose phthalate; maltodextrin; carbomer 934; citric acid; silicon dioxide; xanthan gum; sucrose; povidone; flavour - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 50 mg/ml;   - granules for oral suspension - 250 mg/5ml - active: clarithromycin 50 mg/ml   excipient: carbomer castor oil citric acid monohydrate hydrated silica hypromellose phthalate fruit mix flavour maltodextrin potassium sorbate povidone sucrose titanium dioxide xanthan gum - klacid suspension is indicated for treatment of infections caused by susceptible organisms. such infections include: ? upper respiratory infections (e.g. streptococcal pharyngitis). ? lower respiratory infections (e.g. bronchitis, pneumonia). ? acute otitis media. ? skin and skin structure infections (e.g. impetigo, folliculitis, cellulitis, abscesses). ? disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - granules for oral suspension - 125 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include o lower respiratory tract infections o upper respiratory tract infections o skin and skin structure infections o acute otitis media

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms. indications include:
lower respiratory tract infections for example bronchitis and pneumonia.
upper respiratory tract infections for example sinusitis and pharyngitis.
skin and soft tissue infections for example folliculitis, cellulitis and erysipelas.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - granules for oral suspension - 250 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include: lower respiratory tract infections. upper respiratory tract infections. skin and skin structure infections. acute otitis media.

Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - clarithromycin - granules for oral suspension - clarithromycin 125 mg/5ml - antibacterials for systemic use

Malta - English - Medicines Authority

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - granules for oral suspension - clarithromycin 125 mg/5ml - antibacterials for systemic use

Malta - English - Medicines Authority

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - granules for oral suspension - clarithromycin 250 mg/5ml - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - clarithromycin - granules for oral suspension - macrolides; clarithromycin

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 25 mg/ml;  ;   - granules for oral suspension - 125 mg/5ml - active: clarithromycin 25 mg/ml     excipient: carbomer castor oil citric acid monohydrate fruit mix flavour wl-18758 204264 hydrated silica hypromellose phthalate maltodextrin potassium sorbate povidone sucrose titanium dioxide xanthan gum - klacid suspension is indicated for treatment of infections caused by susceptible organisms. such infections include: ? upper respiratory infections (e.g. streptococcal pharyngitis). ? lower respiratory infections (e.g. bronchitis, pneumonia). ? acute otitis media. ? skin and skin structure infections (e.g. impetigo, folliculitis, cellulitis, abscesses). ? disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii.